Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Kumar S, et al. Among authors: noga sj. Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15. Blood. 2012. PMID: 22422823 Free article. Clinical Trial.
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Kumar SK, et al. Among authors: noga sj. Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27. Leukemia. 2010. PMID: 20508619 Free PMC article. Clinical Trial.
Treating Multiple Myeloma Patients With Oral Therapies.
Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. Kumar SK, et al. Among authors: noga sj. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):243-251. doi: 10.1016/j.clml.2017.02.024. Epub 2017 Mar 7. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28347676 Review.
[No title available]
[No authors listed] [No authors listed] PMID: 36164159
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A. Hari P, et al. Among authors: noga sj. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160. doi: 10.1016/j.clml.2017.12.012. Epub 2018 Jan 5. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29395837 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 36164160
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ. Huff CA, et al. Among authors: noga sj. Biol Blood Marrow Transplant. 2003 May;9(5):312-9. doi: 10.1016/s1083-8791(03)00075-2. Biol Blood Marrow Transplant. 2003. PMID: 12766881 Free article.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda S, Yimer HA, Noga SJ, Girnius S, Yasenchak CA, Charu V, Lyons R, Aiello J, Bogard K, Ferrari RH, Cherepanov D, Demers B, Lu V, Whidden P, Kambhampati S, Birhiray RE, Jhangiani HS, Boccia R, Rifkin RM. Manda S, et al. Among authors: noga sj. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e910-e925. doi: 10.1016/j.clml.2020.06.024. Epub 2020 Jul 6. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32912820 Free PMC article.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
104 results